Abstract
Background
Colorectal cancer (CRC) is one of the frequently diagnosed cancers worldwide. Currently used chemotherapeutic drugs have several side effects. Histone deacetylase (HDAC) enzyme inhibitors possess potential anti-cancer effects. Therefore, we investigated the cytotoxic potential of sodium valproate, a HDAC inhibitor in human colorectal adenocarcinoma (HT-29) cells.
Methods
MTT assay was used to analyze the cytotoxicity of HT-29 cells. Intracellular reactive oxygen species (ROS) induction was evaluated by dichloro-dihydro-fluorescein diacetate staining. Dual staining with acridine orange/ethidium bromide was used to investigate the morphology-related apoptotic cell death. Mitochondrial membrane potential was analyzed by rhodamine 123 staining. E-cadherin protein expression was examined by immunofluorescence staining.
Results
Sodium valproate at 2 and 4 mM/mL treatments significantly induced cytotoxicity. Increased intracellular ROS expression was observed in the cells treated with sodium valproate. This treatment also induced mitochondrial dissipation, apoptosis-related morphological damage, and E-cadherin expression in HT-29 cells.
Conclusions
Our present results suggest that sodium valproate is cytotoxic to HT-29 cells due to its pro-oxidative and apoptosis inducing potential. Sodium valproate can be used as an adjuvant along with standard chemotherapeutic agents in CRC patients after necessary in vivo and clinical studies.
Similar content being viewed by others
References
Sohaib M, Ezhilarasan D. Carbamazepine, a histone deacetylase inhibitor induces apoptosis in human colon adenocarcinoma cell line HT-29. J Gastrointest Cancer. 2020;51(2):564–70.
Gandomani H, Yousefi S, Aghajani M, Mohammadian-Hafshejani A, Tarazoj A, Pouyesh V, et al. Colorectal cancer in the world: incidence, mortality and risk factors. BMRAT. 2017;4(10):1656–75.
Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–91.
Marley AR, Nan H. Epidemiology of colorectal cancer. Int J Mol Epidemiol Genet. 2016;7(3):105–14.
Zhang L, Song R, Gu D, Zhang X, Yu B, Liu B, et al. The role of GLI1 for 5-Fu resistance in colorectal cancer. Cell Biosci. 2017;7:17.
Chen Y, Wang Y, Shi Y, Dai G. Timing of chemotherapy-induced neutropenia predicts prognosis in metastatic colon cancer patients: a retrospective study in mFOLFOX6 -treated patients. BMC Cancer. 2017;17:242.
Metri K, Bhargav H, Chowdhury P, Koka PS. Ayurveda for chemo-radiotherapy induced side effects in cancer patients. J Stem Cells. 2013;8(2):115–29.
Balagura G, Iapadre G, Verrotti A, Striano P. Moving beyond sodium valproate: choosing the right anti-epileptic drug in children. Expert Opin Pharmacother. 2019;20:1449–1456.
Jain A, Haque I, Tayal V, Roy V. Valproic acid-induced acute pancreatitis. Indian J Psychiatry. 2019;61(4):421–2.
Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 2001;276(39):36734–41.
Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 2007;1(1):19–25.
Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014;13(9):673–91.
Sun Y, Sun Y, Yue S, Wang Y, Lu F. Histone deacetylase inhibitors in cancer therapy. Curr Top Med Chem. 2018;18(28):2420–8.
Lakshmaiah KC, Jacob LA, Aparna S, Lokanatha D, Saldanha SC. Epigenetic therapy of cancer with histone deacetylase inhibitors. J Cancer Res Ther. 2014;10(3):469–78.
Ma X, Wang Y, Gu WP, Zhao X. The role and possible molecular mechanism of valproic acid in the growth of MCF-7 breast cancer cells. Croat Med J. 2017;58(5):349–57.
Tong XH, Zheng C, Jiang GJ, Dong SY. Sodium valproate enhances doxorubicin cytotoxicity in breast cancer cells in vitro. Nan Fang Yi Ke Da Xue Xue Bao. 2015;35(1):62–5.
Sargazi S, Saravani R, Zavar Reza J, Jaliani HZ, Mirinejad S, Rezaei Z, et al. Induction of apoptosis and modulation of homologous recombination DNA repair pathway in prostate cancer cells by the combination of AZD2461 and valproic acid. EXCLI J. 2019;18:485–98.
Li H, Zhang Z, Gao C, Wu S, Duan Q, Wu H, et al. Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cells. Cell Biosci. 2019;9:50.
Akgun O, Erkisa M, Ari F. Effective and new potent drug combination: histone deacetylase and Wnt/β-catenin pathway inhibitors in lung carcinoma cells. J Cell Biochem. 2019;120(9):15467–82.
Sanaei M, Kavoosi F. Effect of DNA methyltransferase in comparison to and in combination with histone deacetylase inhibitors on hepatocellular carcinoma HepG2 cell line. Asian Pac J Cancer Prev. 2019;20(4):1119–25.
Zhao Y, You W, Zheng J, Chi Y, Tang W, Du R. Valproic acid inhibits the angiogenic potential of cervical cancer cells via HIF-1α/VEGF signals. Clin Transl Oncol. 2016;18(11):1123–30.
PonselviInduja M, Ezhilarasan D, Ashok Vardhan N. Evolvulus alsinoides methanolic extract triggers apoptosis in HepG2 cells. Avicenna J Phytomed. 2018;8(6):504–12.
Gheena S, Ezhilarasan D. Syringic acid triggers reactive oxygen species-mediated cytotoxicity in HepG2 cells. Hum Exp Toxicol. 2019;38(6):694–702.
Thakur RS, Devaraj E. Lagerstroemia speciosa (L.) Pers. triggers oxidative stress mediated apoptosis via intrinsic mitochondrial pathway in HepG2 cells. Environ Toxicol. 2020. https://doi.org/10.1002/tox.22987.
Fan J, Wang P, Wang X, Tang W, Liu C, Wang Y, et al. Induction of mitochondrial dependent apoptosis in human leukemia K562 cells by Meconopsis integrifolia: a species from traditional Tibetan medicine. Molecules. 2015;20(7):11981–93.
He L, Gao L, Shay C, Lang L, Lv F, Teng Y. Histone deacetylase inhibitors suppress aggressiveness of head and neck squamous cell carcinoma via histone acetylation-independent blockade of the EGFR-Arf1 axis. J Exp Clin Cancer Res. 2019;38(1):84.
Huang M, Zhang J, Yan C, Li X, Zhang J, Ling R. Small molecule HDAC inhibitors: promising agents for breast cancer treatment. Bioorg Chem. 2019;91:103184.
Banik D, Moufarrij S, Villagra A. Immunoepigenetics combination therapies: an overview of the role of HDACs in cancer immunotherapy. Int J Mol Sci. 2019;20(9):E2241.
Luan Y, Li J, Bernatchez JA, Li R. Kinase and histone deacetylase hybrid inhibitors for cancer therapy. J Med Chem. 2019;62(7):3171–83.
Ibrahim N, Buchbinder EI, Granter SR, Rodig SJ, Giobbie-Hurder A, Becerra C, et al. A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma. Cancer Med. 2016;5(11):3041–50.
Duvic M, Dimopoulos M. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: a review of clinical studies. Cancer Treat Rev. 2016;43:58–66.
Eigl BJ, North S, Winquist E, Finch D, Wood L, Sridhar SS, et al. A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195. Investig New Drugs. 2015;33(4):969–76.
Sargazi S, Kooshkaki O, Zavar Reza J, Saravani R, Zarei Jaliani H, Mirinejad S, et al. Mild antagonistic effect of valproic acid in combination with AZD2461 in MCF-7 breast cancer cells. Med J Islam Repub Iran. 2019;33:29.
Rithanya P, Ezhilarasan D. Sodium valproate, a histone deacetylase inhibitor, provokes reactive oxygen species-mediated cytotoxicity in human hepatocellular carcinoma cells. J Gastrointest Cancer. 2020. https://doi.org/10.1007/s12029-020-00370-7.
Ezhilarasan D, Apoorva VS, Ashok Vardhan N. Syzygium cumini extract induced reactive oxygen species-mediated apoptosis in human oral squamous carcinoma cells. J Oral Pathol Med. 2019;48(2):115–21.
Rohit Singh T, Ezhilarasan D. Ethanolic extract of Lagerstroemia speciosa (L.) Pers., induces apoptosis and cell cycle arrest in HepG2 cells. Nutr Cancer. 2020;72:146–156.
Rivera-Del Valle N, Cheng T, Irwin ME, Donnella H, Singh MM, et al. Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations. Cancer Chemother Pharmacol. 2018;81(3):483–95.
Saha SK, Yin Y, Kim K, Yang GM, Dayem AA, Choi HY, et al. Valproic acid induces endocytosis-mediated doxorubicin internalization and shows synergistic cytotoxic effects in hepatocellular carcinoma cells. Int J Mol Sci. 2017;18(5):E1048.
Wang CK, Yu XD, Li Q, Xie G, Teng Y. Chloroquine and valproic acid combined treatment in vitro has enhanced cytotoxicity in an osteosarcoma cell line. Asian Pac J Cancer Prev. 2013;14(8):4651–4.
Koyama M, Izutani Y, Goda AE, Matsui TA, Horinaka M, Tomosugi M, et al. Histone deacetylase inhibitors and 15-deoxy-delta12,14-prostaglandin J2 synergistically induce apoptosis. Clin Cancer Res. 2010;16(8):2320–32.
Sudha A, Srinivasan P, Kanimozhi V, Palanivel K, Kadalmani B. Antiproliferative and apoptosis-induction studies of 5-hydroxy 3′,4′,7-trimethoxyflavone in human breast cancer cells MCF-7: an in vitro and in silico approach. J Recept Signal Transduct Res. 2018;38(3):179–90.
Wasim L, Chopra M. Synergistic anticancer effect of panobinostat and topoisomerase inhibitors through ROS generation and intrinsic apoptotic pathway induction in cervical cancer cells. Cell Oncol (Dordr). 2018;41(2):201–12.
Pistritto G, Trisciuoglio D, Ceci C, Garufi A, D’Orazi G. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. Aging (Albany NY). 2016;8(4):603–19.
Ezhilarasan D. Herbal therapy for cancer. In: Srinivasan P, Shanmugam T, editors. Understanding cancer therapies: CRC Press, Boca Raton; 2018. p. 129–66.
Wong SHM, Fang CM, Chuah LH, Leong CO, Ngai SC. E-cadherin: its dysregulation in carcinogenesis and clinical implications. Crit Rev Oncol Hematol. 2018;121:11–22.
Liu X, Chu KM. E-cadherin and gastric cancer: cause, consequence, and applications. Biomed Res Int. 2014;2014:637308.
Nagle AM, Levine KM, Tasdemir N, Scott JA, Burlbaugh K, Kehm J, et al. Loss of E-cadherin enhances IGF1-IGF1R pathway activation and sensitizes breast cancers to anti-IGF1R/InsR inhibitors. Clin Cancer Res. 2018;24(20):5165–77.
Wang S, Cheng Y, Zheng Y, He Z, Chen W, Zhou W, et al. PRKAR1A is a functional tumor suppressor inhibiting ERK/Snail/E-cadherin pathway in lung adenocarcinoma. Sci Rep. 2016;6:39630.
Zhou P, Wang C, Hu Z, Chen W, Qi W, Li A. Genistein induces apoptosis of colon cancer cells by reversal of epithelial-to-mesenchymal via a Notch1/NF-κB/slug/E-cadherin pathway. BMC Cancer. 2017;17(1):813.
Petrova YI, Schecterson L, Gumbiner BM. Roles for E-cadherin cell surface regulation in cancer. Mol Biol Cell. 2016;27(21):3233–44.
Li Q, Zhou X, Fang Z, Pan Z. Effect of STC2 gene silencing on colorectal cancer cells. Mol Med Rep. 2019;20(2):977–84.
Singh T, Prasad R, Katiyar SK. Therapeutic intervention of silymarin on the migration of non-small cell lung cancer cells is associated with the axis of multiple molecular targets including class 1 HDACs, ZEB1 expression, and restoration of miR-203 and E-cadherin expression. Am J Cancer Res. 2016;6(6):1287–301.
Vasilatos SN, Katz TA, Oesterreich S, Wan Y, Davidson NE, Huang Y. Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells. Carcinogenesis. 2013;34(6):1196–207.
West AC, Christiansen AJ, Smyth MJ, Johnstone RW. The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects. Oncoimmunology. 2012;1(3):377–9.
Yamanegi K, Kawabe M, Futani H, Nishiura H, Yamada N, Kato-Kogoe N, et al. Sodium valproate, a histone deacetylase inhibitor, modulates the vascular endothelial growth inhibitor-mediated cell death in human osteosarcoma and vascular endothelial cells. Int J Oncol. 2015;46(5):1994–2002.
Acknowledgments
The authors wish to thank Anjan Drug Private Limited, Chennai, Tamil Nadu, India, for providing sodium valproate ED as gratis. Special thanks to Dr. S. Gheena, Department of Oral Pathology, Saveetha Dental College and Hospitals, Chennai, India, for the drug procurement procedures.
Author information
Authors and Affiliations
Contributions
ED designed study and analyzed the data and corrected the manuscript. BVMA performed research, acquired the data, and wrote the manuscript.
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare they have no conflict of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Anirudh, B.V.M., Ezhilarasan, D. Reactive Oxygen Species–Mediated Mitochondrial Dysfunction Triggers Sodium Valproate–Induced Cytotoxicity in Human Colorectal Adenocarcinoma Cells. J Gastrointest Canc 52, 899–906 (2021). https://doi.org/10.1007/s12029-020-00505-w
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12029-020-00505-w